Solbinsiran

N/A

Report date: 2026/02/12 20:00:14
NME

Base Information

Drug NameSolbinsiran
Drug Alias NameANGPTL3-siRNA (Eli Lilly and Company)LY-3561774DCR-CM-1DCR-CM1
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAngiopoietin like 3 inhibitorsRNA interference
TargetsAngiopoietin like 3
Therapy Area/IndicationsHypertriglyceridemiaHyperlipoproteinemiasDyslipidemias +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyDicerna Pharmaceuticals IncLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaHyperlipoproteinemiasDyslipidemias +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia